4528 — Ono Pharmaceutical Co Balance Sheet
0.000.00%
- ¥734bn
- ¥676bn
- ¥487bn
- 74
- 73
- 52
- 77
Annual balance sheet for Ono Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
R2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Yuho | Yuho | Yuho | Yuho | Tanshin |
Standards: | IFRS | — | — | — | — |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 104,975 | 116,969 | 164,289 | 204,595 | 210,380 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 84,269 | 99,788 | 114,396 | 136,066 | 135,022 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 247,642 | 281,266 | 345,101 | 413,596 | 455,104 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 113,866 | 112,131 | 108,420 | 104,752 | 105,721 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 745,428 | 739,203 | 882,437 | 913,668 | 1,064,046 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 93,733 | 65,926 | 122,929 | 103,624 | 148,296 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 111,295 | 83,297 | 140,569 | 120,708 | 281,594 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 634,133 | 655,906 | 741,868 | 792,960 | 782,452 |
Total Liabilities & Shareholders' Equity | 745,428 | 739,203 | 882,437 | 913,668 | 1,064,046 |
Total Common Shares Outstanding |